Efruxifermin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Efruxifermin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
11
Registered trials
9
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Efruxifermin can convert its Fc fusion protein profile and FGF21R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Efruxifermin (query alias: Efruxifermin) |
|---|---|
| Modality / target | Fc fusion protein; FGF21R; FGF21R agonists |
| Highest global status | Phase 3 |
| Originator | Amgen, Inc. |
| Active developers | Akero Therapeutics, Inc., University of Iowa Carver College of Medicine |
The MCP disease footprint includes Compensated cirrhosis, Fibrosis, Metabolic Dysfunction Associated Steatohepatitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06528314 | Phase 3 | Recruiting | 2150 | Time from randomization to the first significant clinical event including disease progression, liver decompensation events, etc. |
| NCT06215716 | Phase 3 | Recruiting | 1650 | Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis |
| CTRI/2024/11/076383 | Phase 3 | Open to Recruitment | 1150 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Phase 2; n=181; evaluation: Negative. Reported fields: Composite endpoint(36-week; reduction in fibrosis without worsening of MASH; ITT) = 19 % ; Composite endpoint(36-week; reduction in fibrosis without worsening of MASH; ITT) = 18 % ; Composite endpoint(36-week; reduction in fibrosis without worsening of MASH; ITT) = 13 %
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
Phase 2; n=128; evaluation: not stated. Reported fields: Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3) = 8 Participants ; Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3) = 14 Participants ; Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3): percent difference = 22.6(95% CI, 3.8 - 41.4), P-Value = 0.025; percent difference = 22.5(95% CI, 1.6 - 43.3), P-Value = 0.036
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
Phase 2; n=181; evaluation: Positive. Reported fields: Improvement in fibrosis by at least 1 stage with no worsening of NASH = 29 % ; Improvement in fibrosis by at least 1 stage with no worsening of NASH = 21 % ; Improvement in fibrosis by at least 1 stage with no worsening of NASH = 12 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Efruxifermin addresses Compensated cirrhosis, Fibrosis, Metabolic Dysfunction Associated Steatohepatitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-10-09 | Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion | Phase 3 | US$5,200.0M stated total |
| 2019-10-03 | Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero’s 3D InSight™ Human Liver Disease platform | Phase 1 | Financial terms not disclosed |
| 2018-06-01 | Akero Therapeutics, Inc.acquired exclusive global development and commercialization rights to AKR-001 from Amgen Inc. | Phase 1 | US$120.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pharmaceutical compositions of efruxifermin”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
